Boston Scientific Balance Sheet Health
Financial Health criteria checks 4/6
Boston Scientific has a total shareholder equity of $19.5B and total debt of $9.1B, which brings its debt-to-equity ratio to 46.6%. Its total assets and total liabilities are $35.1B and $15.6B respectively. Boston Scientific's EBIT is $2.4B making its interest coverage ratio 9.9. It has cash and short-term investments of $865.0M.
Key information
46.6%
Debt to equity ratio
US$9.10b
Debt
| Interest coverage ratio | 9.9x |
| Cash | US$865.00m |
| Equity | US$19.53b |
| Total liabilities | US$15.61b |
| Total assets | US$35.14b |
Recent financial health updates
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Recent updates
Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line
Feb 01Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference
Jan 11Boston Scientific to acquire majority stake of Acotec Scientific
Dec 12Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($6.5B) exceed its short term liabilities ($4.9B).
Long Term Liabilities: BSX's short term assets ($6.5B) do not cover its long term liabilities ($10.7B).
Debt to Equity History and Analysis
Debt Level: BSX's net debt to equity ratio (42.2%) is considered high.
Reducing Debt: BSX's debt to equity ratio has reduced from 81.3% to 46.6% over the past 5 years.
Debt Coverage: BSX's debt is well covered by operating cash flow (27.5%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (9.9x coverage).